At the time of writing, UroGen Pharma Ltd [URGN] stock is trading at $20.0, up 4.00%. An important factor to consider is whether the stock is rising or falling in short-term value. The URGN shares have gain 6.72% over the last week, with a monthly amount drifted -12.28%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $36. Previously, H.C. Wainwright upgraded its rating to Buy on June 16, 2025, and kept the price target unchanged to $50. On May 22, 2025, downgrade downgraded it’s rating to Neutral. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $23 on April 16, 2025. Guggenheim started tracking with a Buy rating for this stock on August 22, 2024, and assigned it a price target of $40. In a note dated February 08, 2023, Jefferies downgraded a Hold rating on this stock and revised its target price from $35 to $10.
For the past year, the stock price of UroGen Pharma Ltd fluctuated between $3.42 and $30.00. Currently, Wall Street analysts expect the stock to reach $35.6 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $20.0 at the most recent close of the market. An investor can expect a potential return of 78.0% based on the average URGN price forecast.
Analyzing the URGN fundamentals
According to UroGen Pharma Ltd [NASDAQ:URGN], the company’s sales were 96.52M for trailing twelve months, which represents an 9.04% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.27%, Pretax Profit Margin comes in at -1.56%, and Net Profit Margin reading is -1.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is 1.74 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that UroGen Pharma Ltd [NASDAQ:URGN] has a current ratio of 3.99. On the other hand, the Quick Ratio is 3.79, and the Cash Ratio is 2.13. Considering the valuation of this stock, the price to sales ratio is 9.70.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Nov 19 ’25 when 10000.0 shares were sold. Officer, Schoenberg Mark completed a deal on Nov 19 ’25 to buy 10000.0 shares. Meanwhile, Chief Financial Officer Degnan Chris sold 2203.0 shares on Oct 08 ’25.
